NEW YORK (GenomeWeb) — Finland's Mobidiag announced today that its qualitative qPCR-based Clostridium difficile infection (CDI) test has received CE-IVD marking and is now available throughout Europe.

Called Amplidiag C. difficile+27, the test is able to detect CDI in stool samples by identifying the toxin B gene (tcdB), as well as differentiate the hypervirulence-associated 027 ribotype, in a single reaction.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.